{"title":"1997-2024年英国LGBTQ+人群药物相关死亡特征","authors":"Emmert Roberts, Miriam Hillyard, Caroline Copeland","doi":"10.1111/add.70198","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Individuals from sexual and gender minorities (LGBTQ+) are understudied and at increased and differential risk of experiencing drug-related harms when compared with the general population. We aimed to determine the case characteristics, circumstances of death and type of implicated drugs among LGBTQ+ individuals dying due to drug-related causes. We also aimed to assess any differences between deaths occurring in the context of sexualised vs. non-sexualised drug use.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Coronial records submitted to the National Programme on Substance Use Mortality (NPSUM) in the United Kingdom (UK), 1997-2024.</p><p><strong>Cases: </strong>Decedents identified as LGBTQ+.</p><p><strong>Measurements: </strong>Information was available on decedent sociodemographics, characteristics of death and drugs implicated in death.</p><p><strong>Findings: </strong>A total of 83 decedents were identified as LGBTQ+. Forty-six were identified as cis men (55.4%), four as trans men (4.8%), two as cis women (2.4%) and 31 as trans women (37.3%). Forty-five were identified as gay, including 44 gay men (53.0%) and one gay woman (1.2%), with three identified as bisexual (3.6%). Decedents were predominantly of White ethnicity (n = 68, 81.9%) with a mean age of 38.2 years (standard deviation 12.1; range 16-84). Overall, 16 (19.8%) cases were deemed intentional. Poisoning was the main disease or condition that was certified as the underlying cause of death (n = 46, 55.4%). The median number of drugs implicated in death was 2 [Interquartile range (IQR) 1, 2] with multiple drug toxicity implicated in the majority of cases (n = 42, 50.6%). The two most common drug groups implicated in death were opioids (n = 31, 37.3%) and gamma-hydroxybutyrate (GHB) and related compounds (n = 14, 16.9%). Death occurred in the context of sexualised drug use in 21 cases (25.3%). There were statistically significantly fewer cases in which any opioid (33.9% vs. 4.8%, P = 0.009) or any benzodiazepine (21.0% vs. 0.0%, P = 0.02) were implicated when compared with cases of non-sexualised drug use.</p><p><strong>Conclusions: </strong>Over the last three decades in the United Kingdom there have been consistent numbers of drug-related deaths each year in which individuals were identified as LGBTQ+, results likely representing conservative estimates. A minority of drug-related deaths occurred in the context of sexualised drug use.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics of drug-related deaths among individuals identified as LGBTQ+ in the United Kingdom, 1997-2024.\",\"authors\":\"Emmert Roberts, Miriam Hillyard, Caroline Copeland\",\"doi\":\"10.1111/add.70198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Individuals from sexual and gender minorities (LGBTQ+) are understudied and at increased and differential risk of experiencing drug-related harms when compared with the general population. We aimed to determine the case characteristics, circumstances of death and type of implicated drugs among LGBTQ+ individuals dying due to drug-related causes. We also aimed to assess any differences between deaths occurring in the context of sexualised vs. non-sexualised drug use.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Coronial records submitted to the National Programme on Substance Use Mortality (NPSUM) in the United Kingdom (UK), 1997-2024.</p><p><strong>Cases: </strong>Decedents identified as LGBTQ+.</p><p><strong>Measurements: </strong>Information was available on decedent sociodemographics, characteristics of death and drugs implicated in death.</p><p><strong>Findings: </strong>A total of 83 decedents were identified as LGBTQ+. Forty-six were identified as cis men (55.4%), four as trans men (4.8%), two as cis women (2.4%) and 31 as trans women (37.3%). Forty-five were identified as gay, including 44 gay men (53.0%) and one gay woman (1.2%), with three identified as bisexual (3.6%). Decedents were predominantly of White ethnicity (n = 68, 81.9%) with a mean age of 38.2 years (standard deviation 12.1; range 16-84). Overall, 16 (19.8%) cases were deemed intentional. Poisoning was the main disease or condition that was certified as the underlying cause of death (n = 46, 55.4%). The median number of drugs implicated in death was 2 [Interquartile range (IQR) 1, 2] with multiple drug toxicity implicated in the majority of cases (n = 42, 50.6%). The two most common drug groups implicated in death were opioids (n = 31, 37.3%) and gamma-hydroxybutyrate (GHB) and related compounds (n = 14, 16.9%). Death occurred in the context of sexualised drug use in 21 cases (25.3%). There were statistically significantly fewer cases in which any opioid (33.9% vs. 4.8%, P = 0.009) or any benzodiazepine (21.0% vs. 0.0%, P = 0.02) were implicated when compared with cases of non-sexualised drug use.</p><p><strong>Conclusions: </strong>Over the last three decades in the United Kingdom there have been consistent numbers of drug-related deaths each year in which individuals were identified as LGBTQ+, results likely representing conservative estimates. A minority of drug-related deaths occurred in the context of sexualised drug use.</p>\",\"PeriodicalId\":109,\"journal\":{\"name\":\"Addiction\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Addiction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/add.70198\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/add.70198","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:性少数群体和性别少数群体(LGBTQ+)的个体尚未得到充分研究,与一般人群相比,他们经历药物相关危害的风险增加且存在差异。我们的目的是确定LGBTQ+个体因药物相关原因死亡的病例特征、死亡情况和相关药物类型。我们还旨在评估在性化与非性化吸毒的情况下发生的死亡之间的差异。设计:回顾性队列研究。背景:1997-2024年提交给联合王国国家物质使用死亡率规划(NPSUM)的冠状记录。案例:被认定为LGBTQ+的死者。测量:已获得关于死者的社会人口统计、死亡特征和与死亡有关的药物的信息。调查结果:共有83名死者被确定为LGBTQ+。46人被认定为顺性男性(55.4%),4人被认定为变性男性(4.8%),2人被认定为顺性女性(2.4%),31人被认定为变性女性(37.3%)。45人被认定为同性恋,其中男同性恋44人(53.0%),女同性恋1人(1.2%),双性恋3人(3.6%)。死者主要为白人(n = 68, 81.9%),平均年龄38.2岁(标准差12.1,范围16-84)。总的来说,16例(19.8%)被认为是故意的。中毒是被证实为潜在死亡原因的主要疾病或病症(n = 46, 55.4%)。与死亡相关的药物中位数为2[四分位数间距(IQR) 1,2],大多数病例涉及多种药物毒性(n = 42, 50.6%)。与死亡有关的两个最常见的药物组是阿片类药物(n = 31, 37.3%)和γ -羟基丁酸酯(GHB)及其相关化合物(n = 14, 16.9%)。死亡发生在性毒品使用的背景下,21例(25.3%)。阿片类药物(33.9% vs. 4.8%, P = 0.009)或苯二氮卓类药物(21.0% vs. 0.0%, P = 0.02)与非性别化药物使用病例相比,有统计学意义上显著减少。结论:在过去的三十年中,英国每年都有一致数量的与毒品有关的死亡,其中个人被确定为LGBTQ+,结果可能代表保守估计。少数与毒品有关的死亡发生在性取向吸毒的情况下。
Characteristics of drug-related deaths among individuals identified as LGBTQ+ in the United Kingdom, 1997-2024.
Background and aims: Individuals from sexual and gender minorities (LGBTQ+) are understudied and at increased and differential risk of experiencing drug-related harms when compared with the general population. We aimed to determine the case characteristics, circumstances of death and type of implicated drugs among LGBTQ+ individuals dying due to drug-related causes. We also aimed to assess any differences between deaths occurring in the context of sexualised vs. non-sexualised drug use.
Design: Retrospective cohort study.
Setting: Coronial records submitted to the National Programme on Substance Use Mortality (NPSUM) in the United Kingdom (UK), 1997-2024.
Cases: Decedents identified as LGBTQ+.
Measurements: Information was available on decedent sociodemographics, characteristics of death and drugs implicated in death.
Findings: A total of 83 decedents were identified as LGBTQ+. Forty-six were identified as cis men (55.4%), four as trans men (4.8%), two as cis women (2.4%) and 31 as trans women (37.3%). Forty-five were identified as gay, including 44 gay men (53.0%) and one gay woman (1.2%), with three identified as bisexual (3.6%). Decedents were predominantly of White ethnicity (n = 68, 81.9%) with a mean age of 38.2 years (standard deviation 12.1; range 16-84). Overall, 16 (19.8%) cases were deemed intentional. Poisoning was the main disease or condition that was certified as the underlying cause of death (n = 46, 55.4%). The median number of drugs implicated in death was 2 [Interquartile range (IQR) 1, 2] with multiple drug toxicity implicated in the majority of cases (n = 42, 50.6%). The two most common drug groups implicated in death were opioids (n = 31, 37.3%) and gamma-hydroxybutyrate (GHB) and related compounds (n = 14, 16.9%). Death occurred in the context of sexualised drug use in 21 cases (25.3%). There were statistically significantly fewer cases in which any opioid (33.9% vs. 4.8%, P = 0.009) or any benzodiazepine (21.0% vs. 0.0%, P = 0.02) were implicated when compared with cases of non-sexualised drug use.
Conclusions: Over the last three decades in the United Kingdom there have been consistent numbers of drug-related deaths each year in which individuals were identified as LGBTQ+, results likely representing conservative estimates. A minority of drug-related deaths occurred in the context of sexualised drug use.
期刊介绍:
Addiction publishes peer-reviewed research reports on pharmacological and behavioural addictions, bringing together research conducted within many different disciplines.
Its goal is to serve international and interdisciplinary scientific and clinical communication, to strengthen links between science and policy, and to stimulate and enhance the quality of debate. We seek submissions that are not only technically competent but are also original and contain information or ideas of fresh interest to our international readership. We seek to serve low- and middle-income (LAMI) countries as well as more economically developed countries.
Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.